When it comes to Alzheimer's research, success stories are few and far between. Therapeutic programs center around vaccines and drugs, but Akili Interactive Labs wants to change all that: The Boston-based startup recently signed a deal with Pfizer to see if its mobile video game platform can help diagnose early signs of Alzheimer's.
Three years ago, Roche sent shockwaves ricocheting through the R&D field when it decided to write off a half-billion dollar initiative in RNA drug research and sell off its dedicated facility in Wisconsin. But a year after John Reed took over at Roche's Basel-based research group pRED, Roche is once again doing RNA deals.
Dako has sealed a deal with yet another Big Pharma company to develop companion diagnostic tests for potential new cancer drugs. This time, it will work with Merck, a pharmaceutical giant facing some turmoil as it revamps its struggling R&D operations.
Italian cardiac device giant Sorin will ally with a Chinese competitor to help it grab a stake in China's surging healthcare market.
Vancouver, Canada's Zymeworks has its eyes on a big 2014, signing up with Eli Lilly to lend out its cancer-targeting platform and raising $15 million to advance oncology candidates of its own.
Quest Diagnostics, which is facing a challenging reimbursement environment that's dampening sales, has signed three deals that the New Jersey company says will enhance its ability to develop next-generation diagnostic devices.
Shares of Sangamo BioSciences picked up steam early this morning with the news that Biogen Idec is anteing up $20 million and promising up to $300 million more in milestones to partner with the biotech on new therapies for two inherited blood disorders.
Theorem Clinical Research is looking to up its game in cardiac trials, teaming up with BioTelemetry for access to high-tech core labs and a bigger share of the market.
Global CRO Quintiles has struck up a deal with the Medical Affairs Company, a medical liason contractor, and the two companies plan to pool their powers in drug and device commercialization.
The recently IPO'd Foundation Medicine has expanded its relationship with Novartis, lending out its gene-profiling technology to help the drugmaker develop cancer treatments.